Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...
Milestone Pharmaceuticals (NASDAQ:MIST) Rating Lowered to “Hold” at TD Securities
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) was downgraded by analysts at TD Securities from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday,BayStreet ...
TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty
TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, ...
Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...
Stocktwits on MSN5d
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive
Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...
Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers
Milestone Pharmaceuticals faces a pivotal FDA PDUFA decision for etripamil in PSVT. Read here for a detailed investment ...
US FDA declines to approve Milestone's heart rhythm nasal spray
Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a ...
Why Is Milestone Pharmaceuticals Stock Plunging Today?
Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA ...
MPR1d
FDA Decision on Etripamil Nasal Spray Delayed Due to Nonclinical Issues
The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals regarding the New Drug Application (NDA) for ...
Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil
Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...
Milestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD Cowen
Milestone Pharmaceuticals (MIST – Research Report) received a Hold rating and price target from TD Cowen analyst Ritu Baral today. The ...
Morningstar6d
Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil
Milestone Pharmaceuticals shares collapsed on Friday after the U.S. Food and Drug Administration once again turned away the biopharmaceutical company's proposed etripamil nasal spray to treat a ...